中恒集团(600252.SH)：控股孙公司纳米炭铁混悬注射液联合放疗II期临床试验获得伦理批件

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has successfully passed the ethical review for its self-developed "Nano Carbon Iron Suspension Injection," marking the entry into Phase II clinical trials for combined therapy with radiotherapy [1] Group 1: Clinical Trial Progress - The Phase I clinical trial of Nano Carbon Iron has been completed, focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors [1] - The Ib/IIa phase clinical trial has partially enrolled subjects, with ongoing efficacy follow-ups to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple doses of Nano Carbon Iron in advanced solid tumor patients [1] - The Phase II clinical trial will validate the effectiveness and safety of the drug in combination therapy, providing critical data support for the final product launch application [1] Group 2: Preparatory Work - Yingrui Pharmaceutical is actively preparing for the necessary work before the launch of the research center to ensure the smooth progress of the trials [1]